IgG,MSH6
- Known as:
- Immunoglobulin G,MSH6
- Catalog number:
- 313058
- Product Quantity:
- 0.05 mg
- Category:
- -
- Supplier:
- GenWay
- Gene target:
- IgG MSH6
Related genes to: IgG,MSH6
- Gene:
- MSH6 NIH gene
- Name:
- mutS homolog 6
- Previous symbol:
- GTBP
- Synonyms:
- -
- Chromosome:
- 2p16.3
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-29
- Date modifiied:
- 2019-04-23
Related products to: IgG,MSH6
Alkaline Phosphatase Conjugated Affinity Purified anti-Swine IgG (H&L) [Goat] Secondary_Antibodies Alkaline Phosphatase Conjugated Affinity Purified anti_Swine IgG (H&L) [Goat](5-Lactoglobulin IgG ELISA, Allergies(Arg8)-Vasopressin - Purified Antiserum - IgG(Arg8)-Vasopressin - Purified Antiserum - IgG, Host Rabbit(Arg8)-Vasopressin - Purified Antiserum - IgG, Host Rabbit(Arg8)-Vasopressin - Purified Antiserum - IgG, Host: Rabbit(Arg8)-Vasopressin - Purified Antiserum - IgG, Host: Rabbit(Arg8)_Vasopressin _ Purified Antiserum _ IgG, Host Rabbit(Arg8)_Vasopressin _ Purified Antiserum _ IgG, Host Rabbit(Arg8)_Vasopressin _ Purified Antiserum _ IgG, Host Rabbit(Arg8)_Vasopressin _ Purified Antiserum _ IgG, Host Rabbit(D-Ser(tBu)6,Azagly10)-LHRH (Goserelin) - Purified Antiserum - IgG(D-Ser(tBu)6,Azagly10)-LHRH (Goserelin) - Purified Antiserum - IgG, Host Rabbit(D-Ser(tBu)6,Azagly10)-LHRH (Goserelin) - Purified Antiserum - IgG, Host Rabbit Related articles to: IgG,MSH6
- Comprehensive genomic profiling test (CGPT) using next-generation sequencing (NGS) plays a vital role in cancer diagnosis, treatment option, and prognostic evaluation. In Japan, three tissue-based CGPTs, FoundationOne® CDx, GenMineTOP, and NCC OncoGuide™, are reimbursed under public health insurance. However, their comparative performance in central nervous system (CNS) tumors remains unclear. - Source: PubMed
Publication date: 2026/05/06
Kawauchi DaisukeOhno MakotoTakahashi MasamichiKoyama TakafumiSunami KunikoHirata MakotoYanagisawa ShunsukeOmura TakakiAoki TakumaFujii GentaSaito KojiYamamoto TetsuyaSuzuki HiromichiNarita Yoshitaka - Prostate cancer (PCa) is a heterogeneous and prevalent neoplasm, traditionally stratified by PSA and Gleason Score. However, these biomarkers have prognostic limitations, driving the search for new molecular markers. Alterations in DNA mismatch repair (MMR) system proteins are associated with genomic instability, therapeutic resistance, and poorer clinical outcomes. Their relevance in PCa remains poorly understood, highlighting MMR status as a potential prognostic biomarker. This systematic review, following PRISMA 2020 guidelines, evaluated the relationship between MMR protein (MSH2, MSH6, MLH1, PMS2) expression and clinical-pathological outcomes in PCa. Ten studies assessing MMR protein expression in prostate adenocarcinoma samples were included. Risk of bias was assessed using the Newcastle-Ottawa Scale. Studies revealed heterogeneous MMR protein expression. Loss of MSH2 consistently correlated with poorer clinical outcomes, including biochemical recurrence, higher Gleason Scores, and perineural invasion. MSH6 was more prevalent in high-grade tumors, without clear prognostic association. Cytoplasmic MLH1 expression was linked to aggressive histological patterns; PMS2 results were conflicting. Two studies assessed Microsatellite Instability (MSI), correlating with MSH2 and PMS2. Overall, MMR protein alterations, particularly MSH2 loss, may indicate worse PCa prognosis. However, methodological heterogeneity and lack of standardization hinder definitive conclusions. Further studies, integrating MSI analyses are crucial to confirm their prognostic. - Source: PubMed
Publication date: 2026/05/01
Silva Karina SerafimPasotti Maria Clara Del PintorSouza Luiz Gustavo Neiva ReisLeite Katia Ramos MoreiraReis Sabrina T - This case highlights a novel genotype-phenotype correlation in the field of endocrinology. Specific endocrine and imaging assessment, in addition to next-generation sequencing (NGS), was performed on the Illumina MiSeq platform, using a TruSight One Sequencing Panel kit for genomic analysis of coding regions of 4813 genes. A 54-year-old female was confirmed with a papillary thyroid carcinoma after total thyroidectomy and underwent radioiodine ablative therapy. Three years later, a left femoral enchondroma of almost 3 cm was identified at computed tomography (CT) scan and magnetic resonance imaging (MRI). She experienced hypertension (in addition to obesity, dyslipidaemia and impaired glucose tolerance) and was later confirmed with ACTH-independent cortisol excess [lack of cortisol suppression at 1 mg dexamethasone testing of 13.9 (normal < 1.8 µg/dL)], noting bilateral adrenal tumors, of 4.7 cm (right), respectively, and of 1.6 cm (left) at CT. Right laparoscopic adrenalectomy was performed with post-operative adrenal insufficiency, requiring glucocorticoid replacement and stopping the anti-hypertensive medication. Pathology report confirmed an adrenocortical adenoma (a Ki67 proliferation index of 2%). Noting the unusual association of the mentioned conditions, NGS was performed in the peripheral blood and identified a heterozygote missense variant of the gene (c.5759G>A, p.Arg1920Gln), a heterozygote missense variant of the gene (c.2092C>G, p.Gln698Glu), and an incidental additional finding: a heterozygote stop gain pathogenic variant of the gene (c.2707C>T, p.Arg903*). The first two are currently classified as variants of uncertain significance. Whether the co-presence of a triple mutation may change the clinical picture and the life-long outcomes across reciprocal influence is still an open matter. Further research will point out the clinical implications of this genotype-phenotype association, which, to our best knowledge, has not been previously reported. - Source: PubMed
Publication date: 2026/04/16
Carsote MaraSchipor Sorina VioletaDumitrascu AndaGheorghe Ana-MariaSima Oana-ClaudiaManda DanaCostachescu MihaiMuresan AndreiPreda Emi MarinelaTerzea Dana - TCGA molecular classification has prognostic value in endometrial cancer, but its application in epithelial ovarian cancer is not clear. - Source: PubMed
Publication date: 2026/05/01
Chen Yi-TingLin Po-HanTai Yi-JouHsu Heng-ChengKuo Kuan-TingChiang Ying-Cheng - Current guidelines recommend consideration of germline genetic testing for patients with uterine serous carcinoma (USC) but real-world data are limited on completion rates of testing and pathogenic variant (PV) identification. This study aimed to evaluate the rate of genetic testing referral and completion in a cohort of patients with USC, determine the prevalence of clinically meaningful PVs found on testing and explore factors associated with genetics referral and testing completion. - Source: PubMed
Publication date: 2026/04/29
Tostrud LaurenTurkmen Simge BagciZhang JiaqiHodan RachelKingham KerryDorigo OliverFord James MKurian Allison WGhezelayagh Talayeh S